OTCMKTS:NVZMY Novozymes A/S Earnings Date & Estimates $65.26 +0.97 (+1.51%) As of 10/9/2026 03:59 PM Eastern Novozymes A/S is expected to report earnings on Thursday, November 5, 2026, before market opens. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement Announcement DateNovember 5, 2026TimeBefore Market Opens Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Novozymes A/SNovozymes A/S is expected to post earnings of $0.8220 per share on revenue of $1.31 billion. Novozymes A/S last reported on August 20, 2026, posting $0.44 per share and missing the $0.60 consensus estimate. Novozymes A/S has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS$0.8220Expected Revenue$1.31 billionRecent Track RecordLast ReportedQ2 2026Last Quarter EPS$0.44 (Missed by -$0.16)Last Quarter Revenue$1.30 billionEPS Beat Rate2 of last 8 quartersPrepare for the Earnings CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Novozymes A/S Earnings FAQ When does Novozymes A/S report earnings? Novozymes A/S (OTCMKTS:NVZMY) is estimated to report earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for Novozymes A/S? Analysts expect Novozymes A/S to post earnings of $0.8220 per share for the quarter. How much revenue is Novozymes A/S expected to report? The consensus revenue estimate for Novozymes A/S is $1.31 billion for the quarter. Novozymes A/S Earnings HeadlinesNovozymes A/S (OTCMKTS:NVZMY) vs. Neo Performance Materials (OTCMKTS:NOPMF) Head to Head ReviewOctober 6, 2026 | americanbankingnews.comNovozymes A/S (NVZMY) Q2 2026 Earnings Call TranscriptAugust 20, 2026 | seekingalpha.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 11 at 1:00 AM | Stansberry Research (Ad)Novonesis (Novozymes) B ADR NVZMYAugust 5, 2026 | morningstar.comMNovozymes AS DRC (NVZMY)June 24, 2026 | investing.comA Look At Novozymes (CPSE:NSIS B) Valuation After Recent Share Price WeaknessMay 14, 2026 | uk.finance.yahoo.comSee More Novozymes A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Novozymes A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novozymes A/S and other key companies, straight to your email. Email Address About Novozymes A/SNovozymes A/S (OTCMKTS:NVZMY) was a Danish biotechnology company specializing in biological solutions based on enzymes, microorganisms and related technologies. Its products were designed to help businesses improve manufacturing efficiency, reduce resource use and develop more sustainable alternatives to conventional chemical processes. The company supplied enzyme and microbial products for a range of industries, including household care, food and beverages, agriculture, animal health, bioenergy and industrial manufacturing. Applications included laundry and cleaning products, baking and brewing, starch processing, animal feed, crop-related solutions and the production of biofuels and other biobased materials. Novozymes was established as an independent company in 2000 after being separated from Novo Nordisk and served customers across global markets through research, production and commercial operations in multiple regions. In January 2024, Novozymes combined with Chr. Hansen, another Danish bioscience company, to form Novonesis. Ester Baiget served as Novozymes’ president and chief executive officer before and during the combination process.View Novozymes A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
